Please login to the form below

Not currently logged in
Email:
Password:

adalimumab

This page shows the latest adalimumab news and features for those working in and with pharma, biotech and healthcare.

After FDA refusal, Takeda builds case for subcutaneous Entyvio

After FDA refusal, Takeda builds case for subcutaneous Entyvio

AbbVie’s TNF blocker Humira (adalimumab) in a head-to-head trial.

Latest news

More from news
Approximately 20 fully matching, plus 192 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • NHS medicines optimisation milestone

    that Adalimumab has been opened up to competition from cheaper rivals in Europe. ... prepare for the patent expiry of Adalimumab, which has the highest global turnover of any medicine,.

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. .

  • Biosimilars: Getting the flock to market

    The greatest attraction, naturally, is high-revenue anti-TNF agents like MabThera (rituximab) and Humira (adalimumab), for many years the world's most valuable drug.

  • Wilmington Healthcare Wilmington Healthcare

    Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry.

  • Infographic: RA Perceptions

    expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics